Comparative effect of immunotherapy and standard therapy in patients with high grade glioma: a meta-analysis of published clinical trials

Artene, Ştefan-Alexandru; Turcu-Știolică, Adina; Ciurea, Marius Eugen; Folcuţi, Catalin; Tătăranu, Ligia Gabriela; Alexandru, Oana; Purcaru, O.; Tache, Daniela Elise; Boldeanu, Mihail Virgil; Siloşi, Cristian Adrian; Dricu, Anica

doi:10.1038/s41598-018-30296-x

Cited by 28 publications

(35 citation statements)

References 51 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Systematic reviews and meta-analysis studies of phase I-II clinical trials demonstrated that the addition of dendritic cell vaccines to standard therapy improved the median overall survival and 2- and 3-year survival rates of patients with newly diagnosed or recurrent high-grade gliomas [145,146,147,148,149]. Recent early phase clinical trials largely supported these conclusions (Table 3).…”

Section: Dendritic Cell/peptide Vaccines and Car T-cells For Gliobmentioning

confidence: 97%

Recent Advances in Oncolytic Virotherapy and Immunotherapy for Glioblastoma: A Glimmer of Hope in the Search for an Effective Therapy?

Stepanenko

Chekhonin

2018

Cancers

View full text Add to dashboard Cite

To date, no targeted drugs, antibodies or combinations of chemotherapeutics have been demonstrated to be more efficient than temozolomide, or to increase efficacy of standard therapy (surgery, radiotherapy, temozolomide, steroid dexamethasone). According to recent phase III trials, standard therapy may ensure a median overall survival of up to 18–20 months for adult patients with newly diagnosed glioblastoma. These data explain a failure of positive non-controlled phase II trials to predict positive phase III trials and should result in revision of the landmark Stupp trial as a historical control for median overall survival in non-controlled trials. A high rate of failures in clinical trials and a lack of effective chemotherapy on the horizon fostered the development of conceptually distinct therapeutic approaches: dendritic cell/peptide immunotherapy, chimeric antigen receptor (CAR) T-cell therapy and oncolytic virotherapy. Recent early phase trials with the recombinant adenovirus DNX-2401 (Ad5-delta24-RGD), polio-rhinovirus chimera (PVSRIPO), parvovirus H-1 (ParvOryx), Toca 511 retroviral vector with 5-fluorocytosine, heat shock protein-peptide complex-96 (HSPPC-96) and dendritic cell vaccines, including DCVax-L vaccine, demonstrated that subsets of patients with glioblastoma/glioma may benefit from oncolytic virotherapy/immunotherapy (>3 years of survival after treatment). However, large controlled trials are required to prove efficacy of next-generation immunotherapeutics and oncolytic vectors.

show abstract

Section: Dendritic Cell/peptide Vaccines and Car T-cells For Gliobmentioning

confidence: 97%

Recent Advances in Oncolytic Virotherapy and Immunotherapy for Glioblastoma: A Glimmer of Hope in the Search for an Effective Therapy?

Stepanenko

Chekhonin

2018

Cancers

View full text Add to dashboard Cite

show abstract

“…In recent years, immunotherapies have gained much research attention, and more evidence shows that high-grade gliomas can obtain benefits from the use of immunotherapies [9]. Six meta-analyses published between 2014 and 2018 indicated that improved OS and PFS were obtained via administration of immunotherapy in HGG patients [10][11][12][13][14][15]. To the best of our knowledge, ours is the first meta-analysis to include such detailed subgroup analyses.…”

Section: Introductionmentioning

confidence: 93%

Efficacy and Safety of Immunotherapy and Standard of Care in High-Grade Gliomas: A Systematic Review and Meta-analysis

Zhang

Chen

et al. 2019

Preprint

View full text Add to dashboard Cite

BACKGROUND: Immunotherapy combined with standard of care (SOC) is often used for high-grade glioma (HGG). There are few comparisons of immunotherapy with SOC treatment or without SOC treatment (IMT) versus SOC. It is important to understand what interventions exist and their relative effectivenesses. METHODS: The Cochrane Library, Embase, Medline, and the Web of Science Core Collection were systematically searched by two librarians. Retrieved hits were screened for inclusion. Subgroup analysis was used to examine the main factors associated with overall survival (OS) and progression-free survival (PFS), which were used as primary endpoints to assess the efficacy and safety of IMT. This study was registered with PROSPERO, number CRD42019112356. RESULTS: The search yielded 2,315 results, of which 11 met the eligibility criteria. We identified 6 publications through exploration. Compared to SOC alone, IMT including viral therapy (VT) and dendritic cell vaccination improved the OS (HR = 0.55, 95% CI 0.42-0.72; p < 0.0001) and PFS (HR = 0.67, 95% CI 0.53-0.84; p = 0.0005). CONCLUSIONS: We found that IMT in the era of TMZ has an improved effectiveness over SOC. Our findings support the use of immunotherapy for brain tumors to improve HGG outcomes.

show abstract

“…A number of new immunotherapeutic approaches have been recently developed and examined in GBM. These include immune checkpoint inhibitors, chimeric antigen receptor (CAR) T-cells, and dendritic cell/peptide vaccines (reviewed in [64][65][66][67]). While these approaches show considerable promise, they all currently remain in clinical trials, with the immunosuppressive tumor microenvironment of GBM representing a major barrier.…”

Section: Advances In Treatments For Gbmmentioning

confidence: 99%

Targeting the Sphingolipid System as a Therapeutic Direction for Glioblastoma

Tea

Poonnoose

Pitson

2020

Cancers

View full text Add to dashboard Cite

Glioblastoma (GBM) is the most commonly diagnosed malignant brain tumor in adults. The prognosis for patients with GBM remains poor and largely unchanged over the last 30 years, due to the limitations of existing therapies. Thus, new therapeutic approaches are desperately required. Sphingolipids are highly enriched in the brain, forming the structural components of cell membranes, and are major lipid constituents of the myelin sheaths of nerve axons, as well as playing critical roles in cell signaling. Indeed, a number of sphingolipids elicit a variety of cellular responses involved in the development and progression of GBM. Here, we discuss the role of sphingolipids in the pathobiology of GBM, and how targeting sphingolipid metabolism has emerged as a promising approach for the treatment of GBM.

show abstract

Comparative effect of immunotherapy and standard therapy in patients with high grade glioma: a meta-analysis of published clinical trials

Cited by 28 publications

References 51 publications

Recent Advances in Oncolytic Virotherapy and Immunotherapy for Glioblastoma: A Glimmer of Hope in the Search for an Effective Therapy?

Recent Advances in Oncolytic Virotherapy and Immunotherapy for Glioblastoma: A Glimmer of Hope in the Search for an Effective Therapy?

Efficacy and Safety of Immunotherapy and Standard of Care in High-Grade Gliomas: A Systematic Review and Meta-analysis

Targeting the Sphingolipid System as a Therapeutic Direction for Glioblastoma

Contact Info

Product

Resources

About